Imc Chicago, LLC Editas Medicine, Inc. Transaction History

Imc Chicago, LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 Apr 24, 2023	SELL	$7.03 - $11.53 $239,680 - $393,103	-34,094 Closed	0 $0
Q4 2022 Feb 09, 2023	SELL	$8.32 - $13.21 $374,666 - $594,872	-45,032 Reduced 56.91%	34,094 $302,000
Q3 2022 Nov 08, 2022	SELL	$12.16 - $19.42 $54,476 - $87,001	-4,480 Reduced 5.36%	79,126 $969,000
Q2 2022 Aug 05, 2022	BUY	$9.99 - $21.35 $86,972 - $185,873	8,706 Added 11.62%	83,606 $989,000
Q1 2022 Apr 19, 2022	BUY	$14.08 - $27.63 $364,812 - $715,893	25,910 Added 52.89%	74,900 $1.43 Million
Q4 2021 Feb 08, 2022	BUY	$26.55 - $40.57 $457,403 - $698,939	17,228 Added 54.24%	48,990 $1.3 Million
Q3 2021 Nov 05, 2021	BUY	$39.27 - $72.94 $1.25 Million - $2.32 Million	31,762 New	31,762 $1.31 Million

248

57M

410K

394K

Ticker EDIT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 68,737,200
Market Cap $90M
Description
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads t...

Get notified when there are updates to the investment portfolio of Imc Chicago, LLC, based on Form 13F filings with the SEC.

Stay updated on Imc Chicago, LLC with notifications on news.